MI
KWON KIM
Profesor asociado de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Instituto de Investigación Sanitaria Gregorio Marañón (48)
2024
-
Digital PCR Improves Sensitivity and Quantification in Monitoring CAR-T Cells in B Cell Lymphoma Patients
Transplantation and Cellular Therapy, Vol. 30, Núm. 3, pp. 306.e1-306.e12
-
Financial toxicity in allogeneic haematopoietic stem cell transplant patients from a social determinants of health perspective
European Journal of Oncology Nursing, Vol. 70
-
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217
2023
-
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Leukemia, Vol. 37, Núm. 7, pp. 1511-1520
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study
Cancers, Vol. 15, Núm. 5
-
Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 472.e1-472.e4
-
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (Journal of Hematology & Oncology, (2023), 16, 1, (58), 10.1186/s13045-023-01450-4)
Journal of Hematology and Oncology
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
Journal of Hematology and Oncology, Vol. 16, Núm. 1
-
Novel Candidate loci and Pathogenic Germline Variants Involved in Familial Hematological Malignancies Revealed by Whole-Exome Sequencing
Cancers, Vol. 15, Núm. 3
-
Poor graft function after haploidentical stem cell transplantation with post-transplant cyclophosphamide
Annals of Hematology, Vol. 102, Núm. 6, pp. 1561-1567
-
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation
European Journal of Haematology, Vol. 110, Núm. 6, pp. 659-668
-
Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy
Frontiers in immunology, Vol. 14, pp. 1165759
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
2022
-
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation
Frontiers in immunology, Vol. 13, pp. 1002959
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13
-
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial
The Lancet Haematology, Vol. 9, Núm. 1, pp. e14-e25
-
FLT3-ITD Expression as a Potential Biomarker for the Assessment of Treatment Response in Patients with Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 16